Belzutifan for teenagers with solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests an oral drug called belzutifan in teenagers with certain solid tumors. Belzutifan may shrink tumors by blocking a protein that helps them grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 to 17 years old (adolescent).
- You need to have a certain type of tumor: pheochromocytoma, paraganglioma, wild-type GIST, or tumors caused by von Hippel-Lindau disease.
- Your tumor must be measurable on imaging scans.
- You must not need extra oxygen.
- You must not have taken belzutifan before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
This study gathers information from people with a rare condition called VHL (a genetic disorder that increases the risk of certain tumors) who are taking the drug belzutifan. It looks at how well the drug works and how safe it is over time.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.